Literature DB >> 8861037

Role of two outer membrane antigens in the induction of protective immunity against Francisella tularensis strains of different virulence.

M Fulop1, R Manchee, R Titball.   

Abstract

A crude outer membrane preparation from Francisella tularensis live vaccine strain was used to immunise mice. Immunised mice were completely protected from a F. tularensis challenge. We evaluated the role of two major outer membrane antigens in the induction of protective immunity, namely lipopolysaccharide and an outer membrane protein FopA. We presented FopA to the immune system using an aromatic amino acid dependent Salmonella typhimurium as a vector. Although mice mounted an immune response to cloned FopA no significant protection was induced. However, lipopolysaccharide-immunised mice were completely protected from a F.tularensis live vaccine strain challenge. No increase in LD50 was observed using F. tularensis Schu4 as the challenge strain, although there was a significant increase in time to death. These data question the validity of the murine F. tularensis live vaccine strain model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8861037     DOI: 10.1111/j.1574-695X.1996.tb00245.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  25 in total

1.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

2.  Characterization of Francisella tularensis outer membrane proteins.

Authors:  Jason F Huntley; Patrick G Conley; Kayla E Hagman; Michael V Norgard
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

3.  Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains.

Authors:  Gopi Mara-Koosham; Julie A Hutt; C Rick Lyons; Terry H Wu
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

4.  Physical linkage of naturally complexed bacterial outer membrane proteins enhances immunogenicity.

Authors:  Henriette Macmillan; Junzo Norimine; Kelly A Brayton; Guy H Palmer; Wendy C Brown
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

5.  Linkage between Anaplasma marginale outer membrane proteins enhances immunogenicity but is not required for protection from challenge.

Authors:  Susan M Noh; Joshua E Turse; Wendy C Brown; Junzo Norimine; Guy H Palmer
Journal:  Clin Vaccine Immunol       Date:  2013-02-27

6.  Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.

Authors:  Katharina Richard; Barbara J Mann; Aiping Qin; Eileen M Barry; Robert K Ernst; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2017-03-06

7.  Structural analysis of a protective epitope of the Francisella tularensis O-polysaccharide.

Authors:  Michael J Rynkiewicz; Zhaohua Lu; Julia H Hui; Jacqueline Sharon; Barbara A Seaton
Journal:  Biochemistry       Date:  2012-07-02       Impact factor: 3.162

8.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

9.  Epitope-based vaccination against pneumonic tularemia.

Authors:  Stephen H Gregory; Stephanie Mott; Jennifer Phung; Jinhee Lee; Leonard Moise; Julie A McMurry; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

Review 10.  Rationally designed tularemia vaccines.

Authors:  Barbara J Mann; Nicole M Ark
Journal:  Expert Rev Vaccines       Date:  2009-07       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.